Wang Tao, Qu Xiangyun, Jiang Jiajia, Gao Peng, Zhao Dingding, Lian Xueqi, Li Xiaohua
Key Laboratory of PreMed Precision Medicine, Soochow University, Suzhou, 215121, China.
Jiangsu Provincial Key Laboratory of Molecular Biology and Translational Medicine of Malignant Tumor, Suzhou, 215123, China.
Oncotarget. 2017 Apr 20;8(35):58577-58586. doi: 10.18632/oncotarget.17272. eCollection 2017 Aug 29.
Prostate cancer antigen 3(PCA3) is a long non-coding RNA, which was found increased expression in CaP patients than healthy individual. In this study, the individual nucleic acid of PCA3 and PSA was recombinant expressed as a reference reagent, and a quantitative RT-PCR with TaqMan assay was developed to examine the copies of PCA3 and PSA gene in urine. The results showed that the area under the receiver operating characteristic curve (AUROC) was 0.717, 0.444 and 0.916 for the number of PCA3 copy, PSA copy and for the score of PCA3/PSA RNA, respectively. Additionally, the AUROC for serum tPSA was 0.674 with a low specificity of 12.07%. Finally, the algorithm of PCA3 RNA PSA RNA was evaluated and corroborated as CaP biomarker by conducting a multicentric clinical trial. This study not only validated the developed technique of qRT-PCR with TaqMan assay for examination of urinary PCA3 and PSA RNA, it also demonstrated that the score of the PCA/PSA RNA was a reliable signature for CaP diagnosis.
前列腺癌抗原3（PCA3）是一种长链非编码RNA，研究发现其在前列腺癌患者中的表达高于健康个体。在本研究中，PCA3和PSA的单个核酸被重组表达为参考试剂，并开发了一种TaqMan定量逆转录聚合酶链反应（RT-PCR）来检测尿液中PCA3和PSA基因的拷贝数。结果显示，PCA3拷贝数、PSA拷贝数以及PCA3/PSA RNA评分的受试者工作特征曲线下面积（AUROC）分别为0.717、0.444和0.916。此外，血清总前列腺特异性抗原（tPSA）的AUROC为0.674，特异性低至12.07%。最后，通过多中心临床试验评估并证实了PCA3 RNA/PSA RNA算法可作为前列腺癌生物标志物。本研究不仅验证了用于检测尿液中PCA3和PSA RNA的TaqMan定量RT-PCR技术，还表明PCA/PSA RNA评分是前列腺癌诊断的可靠指标。
